Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma announced it will present clinical trial data from its rare endocrinology programs at ENDO 2026, including two oral presentations and three posters covering hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The presentations will showcase long-term safety and efficacy data for TransCon PTH and benefits of TransCon CNP alone and combined with TransCon hGH in children with achondroplasia.